

**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – March 12, 2008 @ 6:00 p.m.**

Oklahoma Health Care Authority  
4545 N. Lincoln Suite 124  
Oklahoma City, Oklahoma 73105  
**Oklahoma Health Care Authority Board Room**

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. February 13, 2008 DUR Minutes – Vote
  - B. February 14, 2008 DUR Recommendations Memorandum

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman:

4. **Update on DUR/MCAU Program – See Appendix B.**
  - A. Retrospective Drug Utilization Review for November 2007
  - B. Retrospective Drug Utilization Review Response for August 2007
  - C. Medication Coverage Activity Audit for February 2008
  - D. Help Desk Activity Audit for February 2008

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman

5. **Vote to Prior Authorize Combigan™ – See Appendix C.**
  - A. Product Summary
  - B. Cost Comparison
  - C. COP Recommendations

Items to be presented by Dr. Gorman, Dr. McNeill, Chairman:

6. **30 Day Notice to Prior Authorize Narcotic Analgesics – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Browning, Dr. McNeill, Chairman

7. **30 Day Notice to Prior Authorize Tekturna HCT<sup>®</sup> – See Appendix E.**  
A. Product Summary  
B. Cost Comparison  
C. COP Recommendations

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

8. **Fiscal Year 2007 Annual Review – See Appendix F.**  
A. Pharmacy Claims by Therapeutic Category  
B. Top 100 Medications by Pharmacy Reimbursement  
C. Top 50 Medications by Claims

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

9. **Utilization Review of Topical Antibiotics – See Appendix G.**  
A. Utilization Review  
B. Cost Comparison  
C. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman

10. **Vote on New Quantity Limits and Annual Review of Osteoporosis Medications / Bone Resorption Suppression Agents – See Appendix H.**  
A. Introduction / Product Overview  
B. Current PA Criteria  
C. Utilization Review  
D. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

11. **Annual Review of Nasal Allergy Products – See Appendix I.**  
A. Current PA Criteria  
B. Utilization Review  
C. COP Recommendations

12. **FDA and DEA Updates – See Appendix J.**

13. **Future Business**  
A. Oral Allergy Follow-Up  
B. Methylphenidate Follow-Up  
C. Quaaluan Annual Review  
D. Oral Antifungals  
E. New Product Reviews

14. **Adjournment**